Clinical TrialsMerck’s Tulisokibart Shows Strong Phase 3 Efficacy in Ulcerative Colitis Merck’s Tulisokibart Shows Strong Phase 3 Efficacy in Ulcerative Colitis Read Post »
Clinical TrialsCynata’s Pivotal aGvHD and Osteoarthritis Trials Miss Primary Endpoints Cynata’s Pivotal aGvHD and Osteoarthritis Trials Miss Primary Endpoints Read Post »
Clinical TrialsInnovent Advances IBI3003 into Phase 3 Testing for Multiple Myeloma Innovent Advances IBI3003 into Phase 3 Testing for Multiple Myeloma Read Post »
Clinical TrialsMoonLake Reports Strong One-Year Phase 3 Results for Sonelokimab in Hidrade... MoonLake Reports Strong One-Year Phase 3 Results for Sonelokimab in Hidrade... Read Post »
Clinical TrialsRezolute Presents New Ersodetug Analyses Following Mixed Phase 3 Results Rezolute Presents New Ersodetug Analyses Following Mixed Phase 3 Results Read Post »
Clinical TrialsSuven’s Ropanicant Improves Depression Scores in Phase 2b Trial Suven’s Ropanicant Improves Depression Scores in Phase 2b Trial Read Post »
Clinical TrialsSuven’s SUVN-I6107 Shows Early Cognitive Benefits and CNS Activity in Pha... Suven’s SUVN-I6107 Shows Early Cognitive Benefits and CNS Activity in Pha... Read Post »
Clinical TrialsJohnson & Johnson Reports Positive MEMBRANE Trial Results Demonstrating... Johnson & Johnson Reports Positive MEMBRANE Trial Results Demonstrating... Read Post »
Clinical TrialsuniQure Reports Positive Data for AMT-260 in Drug-Resistant Epilepsy uniQure Reports Positive Data for AMT-260 in Drug-Resistant Epilepsy Read Post »
Clinical TrialsFDA Clears IND for CSPC’s Monthly Octreotide in U.S. Acromegaly Trial FDA Clears IND for CSPC’s Monthly Octreotide in U.S. Acromegaly Trial Read Post »
Clinical TrialsEnanta Advances Zelicapavir into Registrational RSV Trial Enanta Advances Zelicapavir into Registrational RSV Trial Read Post »
Clinical TrialsEdgewise Reports Positive Phase 2 CIRRUS-HCM Results for EDG-7500 Edgewise Reports Positive Phase 2 CIRRUS-HCM Results for EDG-7500 Read Post »
Clinical TrialsProJenX Reports Positive Data for First-in-Class CNS-Penetrant Prosetin in ... ProJenX Reports Positive Data for First-in-Class CNS-Penetrant Prosetin in ... Read Post »
Clinical TrialsAlkermes Reports Positive Results for Alixorexton in Narcolepsy Type 2 Alkermes Reports Positive Results for Alixorexton in Narcolepsy Type 2 Read Post »
Clinical TrialsNerandomilast Extends Projected Survival by Up to 5.4 Years in IPF Nerandomilast Extends Projected Survival by Up to 5.4 Years in IPF Read Post »
Clinical TrialsShionogi and F2G Report Positive Phase 3 Results for Olorofim in Invasive A... Shionogi and F2G Report Positive Phase 3 Results for Olorofim in Invasive A... Read Post »
Clinical TrialsHumacyte’s ATEV Improves Dialysis Access and Reduces Infections in Women Humacyte’s ATEV Improves Dialysis Access and Reduces Infections in Women Read Post »
Clinical TrialsBrain Communications Data Show KYGEVVI Reduces Death Risk by Up to 94% in E... Brain Communications Data Show KYGEVVI Reduces Death Risk by Up to 94% in E... Read Post »
Clinical TrialsMIRA Submits Phase 2a Trial Protocol for Ketamir-2 in CIPN MIRA Submits Phase 2a Trial Protocol for Ketamir-2 in CIPN Read Post »
Clinical TrialsBioMarin Reports Long-Term VOXZOGO Growth Benefits in Hypochondroplasia, Ad... BioMarin Reports Long-Term VOXZOGO Growth Benefits in Hypochondroplasia, Ad... Read Post »
Clinical TrialsSedana Medical Files NDA for Isoflurane ICU Sedation System Sedana Medical Files NDA for Isoflurane ICU Sedation System Read Post »
Clinical TrialsFDA Agrees AMT-130 Data Can Support Huntington’s Disease BLA FDA Agrees AMT-130 Data Can Support Huntington’s Disease BLA Read Post »
Clinical TrialsJazz Highlights New Xywav Data Showing Cardiometabolic Benefits and Persona... Jazz Highlights New Xywav Data Showing Cardiometabolic Benefits and Persona... Read Post »
Clinical TrialsRhythm Highlights Long-Term Setmelanotide and Bivamelagon Data Across Rare ... Rhythm Highlights Long-Term Setmelanotide and Bivamelagon Data Across Rare ... Read Post »
Clinical TrialsVYKAT XR Shows Durable Hyperphagia and Behavioral Benefits in PWS VYKAT XR Shows Durable Hyperphagia and Behavioral Benefits in PWS Read Post »
Clinical TrialsOveporexton Improves Daily Functioning and Sleep in Narcolepsy Type 1 Oveporexton Improves Daily Functioning and Sleep in Narcolepsy Type 1 Read Post »
Clinical TrialsNeurocrine Highlights Broad Long-Term Benefits of CRENESSITY Across Adult, ... Neurocrine Highlights Broad Long-Term Benefits of CRENESSITY Across Adult, ... Read Post »
Clinical TrialsAnti-ACTH Antibody Asedebart Shows Strong Cortisol Control in Cushing’s D... Anti-ACTH Antibody Asedebart Shows Strong Cortisol Control in Cushing’s D... Read Post »
Clinical TrialsLegend Biotech Reports First-in-Human Proof-of-Concept for In Vivo CAR-T Cl... Legend Biotech Reports First-in-Human Proof-of-Concept for In Vivo CAR-T Cl... Read Post »
Clinical TrialsIncyte’s INCA033989 Delivers Durable Responses in CALR-Mutated MPNs at EH... Incyte’s INCA033989 Delivers Durable Responses in CALR-Mutated MPNs at EH... Read Post »
Clinical TrialsZilurgisertib Cuts New Bone Formation in FOP, FDA Grants Priority Review Zilurgisertib Cuts New Bone Formation in FOP, FDA Grants Priority Review Read Post »
Clinical TrialsJaypirca Regimen Cuts Progression Risk by 45% in Relapsed CLL Jaypirca Regimen Cuts Progression Risk by 45% in Relapsed CLL Read Post »
Clinical TrialsSun Pharma’s UNLOXCYT™ Delivers Durable Responses in Advanced CSCC Sun Pharma’s UNLOXCYT™ Delivers Durable Responses in Advanced CSCC Read Post »
Clinical TrialsSetmelanotide Lowers BMI and Improves Hyperphagia in Prader-Willi Syndrome Setmelanotide Lowers BMI and Improves Hyperphagia in Prader-Willi Syndrome Read Post »
Clinical TrialsAgios Presents Phase 3 RISE UP Results for Mitapivat in Sickle Cell Disease... Agios Presents Phase 3 RISE UP Results for Mitapivat in Sickle Cell Disease... Read Post »
Clinical TrialsfrontMIND Trial Meets Primary Endpoint in High-Risk DLBCL and HGBL frontMIND Trial Meets Primary Endpoint in High-Risk DLBCL and HGBL Read Post »
Clinical TrialsNovartis’ Rhapsido Delivers Positive Phase 3 Results in CIU Novartis’ Rhapsido Delivers Positive Phase 3 Results in CIU Read Post »
Clinical TrialsCogent Advances Bezuclastinib Toward NDA Submission With Positive APEX Resu... Cogent Advances Bezuclastinib Toward NDA Submission With Positive APEX Resu... Read Post »
Clinical TrialsJazz’s Phase 3 LAGOON Trial Fails to Improve Survival in Relapsed SCL... Jazz’s Phase 3 LAGOON Trial Fails to Improve Survival in Relapsed SCL... Read Post »
Clinical TrialsVenetoclax Plus Obinutuzumab Cuts Risk of Progression or Death by 50% in CL... Venetoclax Plus Obinutuzumab Cuts Risk of Progression or Death by 50% in CL... Read Post »
Clinical TrialsGenmab’s Epcoritamab Plus R2 Maintains Strong Benefit Across Risk Gro... Genmab’s Epcoritamab Plus R2 Maintains Strong Benefit Across Risk Gro... Read Post »
Clinical TrialsCullinan Reports Promising Phase 1 Results for CLN-978 and Velinotamig Cullinan Reports Promising Phase 1 Results for CLN-978 and Velinotamig Read Post »
Clinical TrialsFDA Backs Phase 3 Plan as Enliven Posts Strong Phase 1 CML Results FDA Backs Phase 3 Plan as Enliven Posts Strong Phase 1 CML Results Read Post »
Clinical TrialsZiftomenib + 7+3 Achieves 94% One-Year Survival in NPM1-Mutant AML in KOMET... Ziftomenib + 7+3 Achieves 94% One-Year Survival in NPM1-Mutant AML in KOMET... Read Post »
Clinical TrialsSix-Year SEQUOIA Data Highlight Durable BRUKINSA Benefit in CLL Patients Ag... Six-Year SEQUOIA Data Highlight Durable BRUKINSA Benefit in CLL Patients Ag... Read Post »
Clinical TrialsJohnson & Johnson Strengthens IMAAVY FDA Filing With Positive ENERGY Re... Johnson & Johnson Strengthens IMAAVY FDA Filing With Positive ENERGY Re... Read Post »
Clinical TrialsSanofi Halts Phase 3 MOBILIZE Trial of Riliprubart in Refractory CIDP Sanofi Halts Phase 3 MOBILIZE Trial of Riliprubart in Refractory CIDP Read Post »
Clinical TrialsFDA Aligns on Phase 3 Design for Alterity’s ATH434 in MSA FDA Aligns on Phase 3 Design for Alterity’s ATH434 in MSA Read Post »
Clinical TrialsTango Sets Phase 3 Course for Vopimetostat-Daraxonrasib in MTAP-Deleted PDA... Tango Sets Phase 3 Course for Vopimetostat-Daraxonrasib in MTAP-Deleted PDA... Read Post »
Clinical Trials82% of Patients Respond to BRIUMVI in Early Myasthenia Gravis Study 82% of Patients Respond to BRIUMVI in Early Myasthenia Gravis Study Read Post »
